139 related articles for article (PubMed ID: 28486748)
1. Telomere length is an independent prognostic marker in MDS but not in de novo AML.
Williams J; Heppel NH; Britt-Compton B; Grimstead JW; Jones RE; Tauro S; Bowen DT; Knapper S; Groves M; Hills RK; Pepper C; Baird DM; Fegan C
Br J Haematol; 2017 Jul; 178(2):240-249. PubMed ID: 28486748
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome.
Park HS; Choi J; See CJ; Kim JA; Park SN; Im K; Kim SM; Lee DS; Hwang SM
Ann Lab Med; 2017 May; 37(3):195-203. PubMed ID: 28224765
[TBL] [Abstract][Full Text] [Related]
3. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes.
Ohyashiki JH; Iwama H; Yahata N; Ando K; Hayashi S; Shay JW; Ohyashiki K
Clin Cancer Res; 1999 May; 5(5):1155-60. PubMed ID: 10353751
[TBL] [Abstract][Full Text] [Related]
4. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
[TBL] [Abstract][Full Text] [Related]
5. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
6. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups.
Gadji M; Adebayo Awe J; Rodrigues P; Kumar R; Houston DS; Klewes L; Dièye TN; Rego EM; Passetto RF; de Oliveira FM; Mai S
Clin Cancer Res; 2012 Jun; 18(12):3293-304. PubMed ID: 22539801
[TBL] [Abstract][Full Text] [Related]
7. Cancer and myeloid clonal evolution in the short telomere syndromes.
Schratz KE; Armanios M
Curr Opin Genet Dev; 2020 Feb; 60():112-118. PubMed ID: 32276199
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Akimoto M; Sakurai A; Nishiyama-Fujita Y; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2021 Apr; 100(4):953-957. PubMed ID: 33521864
[TBL] [Abstract][Full Text] [Related]
9. Morphological comparison of dysplastic changes between de novo acute myeloid leukemia (AML) with trilineage myelodysplasia and AML developed from de novo myelodysplastic syndromes.
Kuriyama K; Miyazaki Y; Arimura K; Nagai K; Nakamura H; Matsuo T; Tomonaga M
Leuk Res; 1995 Feb; 19(2):121-5. PubMed ID: 7869740
[TBL] [Abstract][Full Text] [Related]
10. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Miesner M; Haferlach C; Bacher U; Weiss T; Macijewski K; Kohlmann A; Klein HU; Dugas M; Kern W; Schnittger S; Haferlach T
Blood; 2010 Oct; 116(15):2742-51. PubMed ID: 20581309
[TBL] [Abstract][Full Text] [Related]
11. Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.
Oosterveld M; Suciu S; Muus P; Germing U; Delforge M; Belhabri A; Aul C; Selleslag D; Ferrant A; Marie JP; Amadori S; Jehn U; Mandelli F; Hess U; Hellström-Lindberg E; Cakmak-Wollgast S; Vignetti M; Labar B; Willemze R; de Witte T
Ann Hematol; 2015 Jan; 94(1):23-34. PubMed ID: 25096636
[TBL] [Abstract][Full Text] [Related]
12. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
13. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.
Chakraborty S; Sun CL; Francisco L; Sabado M; Li L; Chang KL; Forman S; Bhatia S; Bhatia R
J Clin Oncol; 2009 Feb; 27(5):791-8. PubMed ID: 19124806
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
Wang H; Zhang N; Wu X; Zheng X; Ling Y; Gong Y
Ann Hematol; 2019 Dec; 98(12):2629-2639. PubMed ID: 31754743
[TBL] [Abstract][Full Text] [Related]
15. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation.
Ohyashiki K; Iwama H; Yahata N; Tauchi T; Kawakubo K; Shimamoto T; Ohyashiki JH
Leuk Lymphoma; 2001 Jul; 42(3):291-9. PubMed ID: 11699393
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
17. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
Schanz J; Tüchler H; Solé F; Mallo M; Luño E; Cervera J; Granada I; Hildebrandt B; Slovak ML; Ohyashiki K; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Valent P; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Faderl S; Pierce S; Le Beau MM; Bennett JM; Greenberg P; Germing U; Haase D
J Clin Oncol; 2012 Mar; 30(8):820-9. PubMed ID: 22331955
[TBL] [Abstract][Full Text] [Related]
18. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
19. Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome.
Poloni A; Serrani F; Berardinelli E; Maurizi G; Mariani M; Costantini B; Trappolini S; Mancini S; Olivieri A; Leoni P
Leuk Res; 2013 Nov; 37(11):1538-44. PubMed ID: 24095110
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]